US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

November 24, 2017: By Jon Swedien
RxSight's Light Adjustable Lens

RxSight’s Light Adjustable Lens

The US FDA has approved RxSight’s Light Adjustable Lens (RxLAL) and Light Delivery Device (LDD), the agency announced Nov. 22.

The RxSight IOL is made of a material that reacts to UV light, which is delivered using the LDD after surgery. It is the first system that can make small adjustments to an artificial lens’ power after cataract surgery so patients have better vision when not using glasses, the FDA said.

The device is intended for patients who have astigmatism in the cornea and no macular disease, the FDA said.

Residual refractive error, even after premium cataract surgery, is still common due to unpredictable wound healing, as well as variations in postoperative lens position. The RxLAL allows for in-office optimization after lens implantation and wound healing takes place, RxSight said.

The RxLAL is implanted like any standard foldable monofocal IOL, so there is no additional learning curve or time added to the procedure, RxSight said.

A surgeon can postoperatively expose the implanted lens to the frequency and amount of light needed to reshape the lens and achieve the desired vision, based upon patient feedback. Patients receive three or four light treatments, each lasting about 40 to 150 seconds. Then, the correction is locked in, the company said.

Patients must wear special eyeglasses for UV protection from the time of the cataract surgery to the end of the light treatments to protect the new lens from UV light in the environment, the FDA said.

In a clinical study of 600 patients evaluating the RxLAL and LDD, patients saw improvement of about one line for distance vision without glasses at six months compared with a conventional IOL, and 75 percent had a reduction in astigmatism, the FDA said.

The FDA said the device should not be used in patients taking systemic medication that may increase sensitivity to UV light such as tetracycline, doxycycline, psoralens, amiodarone, phenothiazines, chloroquine, hydrochlorothiazide, hypercin, ketoprofen, piroxicam, lomefloxacin and methoxsalen. Treatment in patients taking such medications may lead to irreversible eye damage. The device is also contraindicated in cases where patients have a history of ocular herpes simplex virus, the agency said.

Going forward, RxSight plans to focus on its postmarket study, additional indications, platform improvements, and building scalable infrastructure, said Eric Weinberg, the company’s COO.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023